Endo, Impax Move To Trim Opana Pay-For-Delay MDL
By Kevin Penton ( April 11, 2016, 2:49 PM EDT) -- Pharmaceutical giants Endo and Impax urged an Illinois federal court Friday to partially dismiss state antitrust claims refiled by a putative class of end-payors who allege in multidistrict litigation that the pair engaged in a pay-for-delay scheme involving a generic version of the opioid pain medication Opana ER....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.